Thor Voigt
Boehringer Ingelheim (Canada)(CA)Boehringer Ingelheim (United States)(US)
Publications by Year
Research Areas
Acute Ischemic Stroke Management, Immunotherapy and Immune Responses, Antiplatelet Therapy and Cardiovascular Diseases, Stroke Rehabilitation and Recovery, CAR-T cell therapy research
Most-Cited Works
- → Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent Stroke(2008)965 cited
- → Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events(2008)778 cited
- → Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study(2008)357 cited
- → Immunotherapy of Metastatic Malignant Melanoma by a Vaccine Consisting of Autologous Interleukin 2-Transfected Cancer Cells: Outcome of a Phase I Study(1999)127 cited
- → Phase I Study to the Immunotherapy of Metastatic Malignant Melanoma by a Cancer Vaccine Consisting of Autologous Cancer Cells Transfected with the Human IL-2 Gene. University of Vienna, Austria(1996)39 cited
- → Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene(1997)14 cited
- Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFE(2008)
- → Comparison of oral itasetron with oral ondansetron(1997)6 cited
- → Itasetron hydrochloride (DAU 6215Cl): A pharmacoklnetlcally unique 5-HT3 antagonist(1997)
- → Oral itasetron hydrochloride (DAU 6215Cl) versus ondansetron (OND): Comparable efficacy at a lower dose(1997)